Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of one systematic review(s)/meta-analysis(es). ^[1]
• The overall mean improvement in MG-ADL score across all evaluated treatments was -2.17 points (95% CI -2.67, -1.67; p < 0.001).
• No significant difference was found between complement inhibitors (such as eculizumab, ravulizumab) and anti-FcRn treatments (efgartigimod, rozanolixizumab) (p = 0.16), while rituximab did not significantly improve the MG-ADL score (-0.92 [95% CI -2.24, 0.39]; p = 0.17).
• The overall mean improvement in the QMG score was -3.46 points (95% CI -4.53, -2.39; p < 0.001). Anti-FcRn treatments showed a greater reduction in QMG score (-4.78) compared to complement inhibitors (-2.60; p < 0.001).
• Rituximab did not result in a significant improvement in QMG score (-1.9 [95% CI -3.97, 0.18]; p = 0.07).
• Among the drugs assessed, efgartigimod had the highest probability of being the most effective, followed by rozanolixizumab, based on network meta-analysis, while rituximab showed no significant benefit in improving MG-ADL or QMG scores.
• There is no safety information available in the reviewed documents.
• The studies primarily focused on patients with Myasthenia Gravis (MG) across various treatment durations: 12 weeks for zilucoplan, 26 weeks for eculizumab and ravulizumab, 28 days for efgartigimod, 43 days for rozanolixizumab, and 16 to 52 weeks for rituximab. There were no specific findings reported for subgroups, such as age, gender, or comorbid conditions, in the provided documents.